These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27564104)

  • 1. Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing.
    Wang Y; Tian PW; Wang WY; Wang K; Zhang Z; Chen BJ; He YQ; Li L; Liu H; Chuai S; Li WM
    Oncotarget; 2016 Oct; 7(40):65208-65217. PubMed ID: 27564104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.
    Cui S; Zhang W; Xiong L; Pan F; Niu Y; Chu T; Wang H; Zhao Y; Jiang L
    Oncotarget; 2017 Jan; 8(2):2771-2780. PubMed ID: 27926526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.
    Kwon M; Ku BM; Olsen S; Park S; Lefterova M; Odegaard J; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Med; 2022 Aug; 11(15):2944-2956. PubMed ID: 35437925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Zhou X; Shou J; Sheng J; Xu C; Ren S; Cai X; Chu Q; Wang W; Zhen Q; Zhou Y; Li W; Pan H; Li H; Sun T; Cheng H; Wang H; Lou F; Rao C; Cao S; Pan H; Fang Y
    Cancer Sci; 2019 Oct; 110(10):3382-3390. PubMed ID: 31444835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative detection of ALK fusion breakpoints in plasma cell-free DNA from patients with non-small cell lung cancer using PCR-based target sequencing with a tiling primer set and two-step mapping/alignment.
    Kunimasa K; Kato K; Imamura F; Kukita Y
    PLoS One; 2019; 14(9):e0222233. PubMed ID: 31513617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
    Velizheva NP; Rechsteiner MP; Valtcheva N; Freiberger SN; Wong CE; Vrugt B; Zhong Q; Wagner U; Moch H; Hillinger S; Schmitt-Opitz I; Soltermann A; Wild PJ; Tischler V
    Pathol Res Pract; 2018 Apr; 214(4):572-578. PubMed ID: 29580750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
    Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
    Guibert N; Hu Y; Feeney N; Kuang Y; Plagnol V; Jones G; Howarth K; Beeler JF; Paweletz CP; Oxnard GR
    Ann Oncol; 2018 Apr; 29(4):1049-1055. PubMed ID: 29325035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in
    Dietz S; Christopoulos P; Gu L; Volckmar AL; Endris V; Yuan Z; Ogrodnik SJ; Zemojtel T; Heussel CP; Schneider MA; Meister M; Muley T; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
    Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31753813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.
    Ai X; Niu X; Chang L; Chen R; Ou SI; Lu S
    Lung Cancer; 2018 Sep; 123():83-86. PubMed ID: 30089600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
    Won JK; Keam B; Koh J; Cho HJ; Jeon YK; Kim TM; Lee SH; Lee DS; Kim DW; Chung DH
    Ann Oncol; 2015 Feb; 26(2):348-54. PubMed ID: 25403583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis.
    Zhao R; Zhang J; Han Y; Shao J; Zhu L; Xiang C; Zhang Q; Teng H; Qin G; Zhao L; Ye M; Zhao J; Ding W
    Mol Diagn Ther; 2019 Jun; 23(3):395-405. PubMed ID: 30840206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer.
    Lee Y; Cho Y; Park EY; Park SY; Hwang KH; Han JY
    Oncologist; 2021 Oct; 26(10):e1683-e1692. PubMed ID: 34272914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
    Hembrough T; Liao WL; Hartley CP; Ma PC; Velcheti V; Lanigan C; Thyparambil S; An E; Monga M; Krizman D; Burrows J; Tafe LJ
    Clin Chem; 2016 Jan; 62(1):252-61. PubMed ID: 26585927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.
    Xia P; Zhang L; Li P; Liu E; Li W; Zhang J; Li H; Su X; Jiang G
    J Transl Med; 2021 Jul; 19(1):308. PubMed ID: 34271921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
    Ignatius Ou SH; Azada M; Hsiang DJ; Herman JM; Kain TS; Siwak-Tapp C; Casey C; He J; Ali SM; Klempner SJ; Miller VA
    J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
    Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
    Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
    J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.